Cinqaero, also known by its generic name reslizumab, is a prescription medication used in the treatment of severe eosinophilic asthma in adults. It is a type of biologic therapy, specifically a monoclonal antibody, designed to target and reduce levels of interleukin-5 (IL-5), a key protein that plays a crucial role in the growth, activation, and survival of eosinophils, a type of white blood cell involved in the pathophysiology of asthma. By inhibiting IL-5, Cinqaero helps to decrease the number of eosinophils, thereby reducing inflammation, asthma attacks, and improving breathing in patients who have not responded well to other asthma treatments. Cinqaero is administered through intravenous infusion under the guidance of a healthcare professional.